🚀 VC round data is live in beta, check it out!
Liquidia Valuation Multiples
Discover revenue and EBITDA valuation multiples for Liquidia and similar public comparables like Ab&B Bio-Tech, Hisamitsu Pharmaceutical, China Res Double-Crane, SK Bioscience and more.
Liquidia Overview
About Liquidia
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Founded
2004
HQ
Employees
170
Website
Sectors
Financials (LTM)
EV
$3B
Liquidia Financials
Liquidia reported last 12-month revenue of $251M.
In the same LTM period, Liquidia generated $230M in gross profit and had net loss of ($5M).
Revenue (LTM)
Liquidia P&L
In the most recent fiscal year, Liquidia reported revenue of $158M and EBITDA of ($43M).
Liquidia expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $251M | XXX | $158M | XXX | XXX | XXX |
| Gross Profit | $230M | XXX | $145M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 92% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($43M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (27%) | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | (32%) | XXX | XXX | XXX |
| Net Profit | ($5M) | XXX | ($69M) | XXX | XXX | XXX |
| Net Margin | (2%) | XXX | (44%) | XXX | XXX | XXX |
| Net Debt | — | — | $661K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Liquidia Stock Performance
Liquidia has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Liquidia's stock price is $30.94.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.0% | XXX | XXX | XXX | $-0.79 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLiquidia Valuation Multiples
Liquidia trades at 10.9x EV/Revenue multiple, and (63.2x) EV/EBITDA.
EV / Revenue (LTM)
Liquidia Financial Valuation Multiples
As of March 21, 2026, Liquidia has market cap of $3B and EV of $3B.
Equity research analysts estimate Liquidia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Liquidia has a P/E ratio of (531.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 10.9x | XXX | 17.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (63.2x) | XXX | XXX | XXX |
| EV/EBIT | 164.5x | XXX | (53.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 11.9x | XXX | 18.8x | XXX | XXX | XXX |
| P/E | (531.7x) | XXX | (39.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (65.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Liquidia Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Liquidia Margins & Growth Rates
Liquidia's revenue in the last 12 month grew by 163%.
Liquidia's revenue per employee in the last FY averaged $1.5M.
Liquidia Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 163% | XXX | 271% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (27%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (942%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 99% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 19% | XXX | 25% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 124% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Liquidia Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Ab&B Bio-Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| Hisamitsu Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| China Res Double-Crane | XXX | XXX | XXX | XXX | XXX | XXX |
| SK Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Travere Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Liquidia M&A Activity
Liquidia acquired XXX companies to date.
Last acquisition by Liquidia was on XXXXXXXX, XXXXX. Liquidia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Liquidia
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLiquidia Investment Activity
Liquidia invested in XXX companies to date.
Liquidia made its latest investment on XXXXXXXX, XXXXX. Liquidia invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Liquidia
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Liquidia
| When was Liquidia founded? | Liquidia was founded in 2004. |
| Where is Liquidia headquartered? | Liquidia is headquartered in United States. |
| How many employees does Liquidia have? | As of today, Liquidia has over 170 employees. |
| Who is the CEO of Liquidia? | Liquidia's CEO is Roger A. Jeffs. |
| Is Liquidia publicly listed? | Yes, Liquidia is a public company listed on Nasdaq. |
| What is the stock symbol of Liquidia? | Liquidia trades under LQDA ticker. |
| When did Liquidia go public? | Liquidia went public in 2018. |
| Who are competitors of Liquidia? | Liquidia main competitors are Ab&B Bio-Tech, Hisamitsu Pharmaceutical, China Res Double-Crane, SK Bioscience. |
| What is the current market cap of Liquidia? | Liquidia's current market cap is $3B. |
| What is the current revenue of Liquidia? | Liquidia's last 12 months revenue is $251M. |
| What is the current revenue growth of Liquidia? | Liquidia revenue growth (NTM/LTM) is 163%. |
| What is the current EV/Revenue multiple of Liquidia? | Current revenue multiple of Liquidia is 10.9x. |
| Is Liquidia profitable? | No, Liquidia is not profitable. |
| What is the current net income of Liquidia? | Liquidia's last 12 months net income is ($5M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.